PO.SHP01.02 · 科学与健康政策
MATCHMAKERS 癌症大挑战团队：以伙伴关系和使命最大化患者研究倡导者对协作性临床前研究的参与
MATCHMAKERS Cancer Grand Challenge Team: Partnership and purpose to maximize patient research advocate involvement in collaborative preclinical research
该海报暂无可下载的资料
AACR 官方页面
作者与单位 Authors & Affiliations
摘要 Abstract
中文摘要
目的 患者研究倡导者（PRA）对临床试验的参与已有所增加，但对临床前研究的参与仍然有限，因为纳入患者视角的路径并不总是明确。MATCHMAKERS 旨在构建 PRA 有效参与临床前科学的模型。
背景 由 NCI 和 CRUK 创立的癌症大挑战（CGC）支持全球跨学科团队推进癌症研究，并要求患者倡导者参与以确保现实影响。CGC MATCHMAKERS 团队于 2024 年启动，包括来自六个国家 10 家机构的研究人员，致力于利用结构生物学、高通量筛选和人工智能破解 T 细胞识别癌细胞的密码，为预测性免疫治疗工具提供依据。
方法 来自美国和巴西的四位 PRA 贡献了亲历的癌症经验和倡导专长。PRA 参加每月研究会议、PRA 会议、CGC 倡导者会议以及年度 CGC 和 MATCHMAKERS 峰会。首席 PI 和项目经理参加 PRA 会议，并协调与受训人员和研究者的互动，以促进双向学习和参与。
结果 PRA 已与来自四个实验室的五名受训人员建立伙伴关系，共同开发了共享语言、情境和沟通工具。PRA 的参与加强了对 MATCHMAKERS 研究目标的理解，同时受训人员报告了对患者需求和转化相关性的重视。关键活动和受训人员的反思总结于表中。
结论 早期经验表明，结构化的 PRA 参与培育了相互尊重、信任以及更以患者为中心的科学思维。下一步包括跨机构扩展 PRA 与受训人员的伙伴关系，并为 CGC 范围内制定 PRA 参与临床前研究的最佳实践做出贡献。
PRA 目标、关键产出和受训人员反思 类别
PRA 目标 将患者视角带入研究；支持受训人员教育；与患者社群分享 MATCHMAKERS 科学；为临床前倡导制定最佳实践 产出 术语表；通俗易懂的摘要；通俗的 TCR 概述；面向倡导者的教育模块；实验室参访视频系列 受训人员反思 “我更多地思考基础研究之外的适用性。”
“倡导者的意见让我始终专注于临床转化。”
“这种参与帮助我看到更宏大的目的并更好地沟通。”
查看英文原文 English abstract
Objectives Patient research advocate (PRA) involvement in clinical trials has increased, yet involvement in pre-clinical research remains limited because pathways for incorporating patient perspectives are not always clear. MATCHMAKERS seeks to build models for effective PRA participation in pre-clinical science.
Background Cancer Grand Challenges (CGC), founded by NCI and CRUK, supports global interdisciplinary teams advancing cancer research and requires patient advocate involvement to ensure real-world impact. Launched in 2024, CGC Team MATCHMAKERS includes researchers from 10 institutions across six countries working to crack the code of how T cells recognize cancer cells using structural biology, high-throughput screening, and artificial intelligence to inform predictive immunotherapy tools.
Methods Four PRAs from the USA and Brazil contribute lived cancer experience and advocacy expertise. PRAs attend monthly research meetings, PRA meetings, CGC advocate sessions, and annual CGC and MATCHMAKERS summits. The Lead PI and Program Manager attend PRA meetings and coordinate interactions with trainees and investigators to facilitate bidirectional learning and involvement.
Results PRAs have partnered with five trainees from four labs, co-developing shared language, context, and communication tools. PRA involvement has strengthened understanding of MATCHMAKERS research goals, while trainees report appreciation of patient needs and translational relevance. Key activities and trainee reflections are summarized in the Table.
Conclusions Early experience demonstrates that structured PRA involvement fosters mutual respect, trust, and more patient-centered scientific thinking. Next steps include expanding PRA-trainees partnerships across institutions and contributing to CGC-wide best-practice development for PRA involvement in pre-clinical research.
PRA goals, key outputs, and trainee reflections Category
PRA Goals Bring patient perspective into research; support trainee education; share MATCHMAKERS science with patient communities; develop best practices for pre-clinical advocacy Outputs Glossary; lay summaries; lay TCR overview; education module for advocates; lab-visit video series Trainee Reflections “I think more about applicability beyond fundamental research.”
“Advocacy input keeps me focused on clinical translation.”
“Engagement helps me see the broader purpose and communicate better.”
利益披露 Disclosure
A. Ellis, None..
L. Holtz, None..
M. Rakoff, None..
T. Solak, None..
M. O. de Souza, None.
M. Birnbaum,
Kelonia Therapeutics g., Board of Directors, non-salaried role), Stock.
Pfizer ).